Targacept, Inc.

Targacept, Inc., a biopharmaceutical company, engages in the discovery, design, and development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its products include TC-5214, a nicotinic channel modulator, which is in Phase III clinical trials as an adjunct treatment for depressive disorder; and in Phase IIb clinical trial for switch monotherapy in patients with depressive disorder.

Ticker:
TRGT
Exchange:
NASDAQ (See More NASDAQ Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?